FDA Gears Up Real-Time Trials Fueled by AI to Accelerate Drug Development
TL;DR Summary
The FDA will speed drug development by reviewing real-time trial data from AstraZeneca and Amgen and is seeking public input on a pilot using AI to improve safety monitoring, dosing, and recruitment. The efforts include AZ’s Phase 2 lymphoma trial at MD Anderson and UPenn, and Amgen’s Phase 1b small cell lung cancer study, all supported by Paradigm Health’s real-time data platform.
Topics:business#artificial-intelligence#astrazeneca#clinical-trials#fda#health-policy#paradigm-health
- FDA launches effort to speed up clinical trials, using AI statnews.com
- FDA Turns to AI to Speed Up Clinical Trials WSJ
- FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board Fierce Biotech
- FDA Plans to Speed Up Drug Trials With Real-Time Data, AI Bloomberg.com
- FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development statnews.com
Reading Insights
Total Reads
0
Unique Readers
23
Time Saved
2 min
vs 3 min read
Condensed
86%
448 → 62 words
Want the full story? Read the original article
Read on statnews.com